Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005
Omission of Financial Disclosure. In the Original Investigation by De Serres et al titled “Recurrence Risk of Oculorespiratory Syndrome After Influenza Vaccination: Randomized Controlled Trial of Previously Affected Persons,” published in the November 8 issue of the ARCHIVES (2004;164:2266-2272), the Financial Disclosure was inadvertently omitted on page 2266. The statement of Financial Disclosure should have appeared beneath the Author Affiliations and read as follows: “Financial Disclosure: Drs De Serres, Skowronski, and Duval have received research grants and Dr Skowronski has received honoraria from Aventis Pasteur and Shire Biologics. Dr Guay has received grants from Wyeth-Ayerst Canada, Biochem Pharma, and Merck Frosst Canada.” The journal regrets the error.
Recurrence Risk of Oculorespiratory Syndrome After Influenza Vaccination: Randomized Controlled Trial of Previously Affected Persons—Correction. Arch Intern Med. 2005;165(2):145. doi:10.1001/archinte.165.2.145